What is Eternatear?
EternaTear is a specialized biotechnology firm dedicated to the development of next-generation artificial tears designed to provide sustained relief for patients suffering from dry eye syndrome. By utilizing a unique, bio-mimetic mechanism, the company's product offers an extended duration of action, effectively reducing the frequency of application required by patients. This innovation represents a significant departure from traditional over-the-counter solutions, positioning EternaTear as a disruptive force in the ocular therapeutic market. The company's focus on high-efficacy, long-lasting relief addresses the debilitating symptoms that impact the daily quality of life for millions of individuals globally.
How much funding has Eternatear raised?
Eternatear has raised a total of $4.9M across 1 funding round:
Series A
$4.9M
Series A (2020): $4.9M with participation from Carolina Angel Network LLC, Duke Angel Network, Band of Angels, Deep Work Capital, Keiretsu Forum, and Keiretsu Capital
Key Investors in Eternatear
Band of Angels
Band of Angels is Silicon Valley's oldest angel investment group, consisting of over 150 active angel investors who are primarily former and current high-tech executives. The group focuses on high technology and life sciences, providing both capital and mentorship to early-stage startups.
Keiretsu Forum
Keiretsu Forum is a global investment community comprised of angel investors, venture capitalists, and serial entrepreneurs, providing early-stage capital and strategic networking opportunities.
Keiretsu Capital
Keiretsu Capital serves as the investment arm of the Keiretsu Forum, focusing on institutional-grade deal flow and supporting high-growth startups through its extensive network of professional investors.
What's next for Eternatear?
With the successful closure of this major enterprise-level funding, EternaTear is poised to enter a phase of rapid commercialization and clinical validation. The strategic roadmap includes expanding its clinical trial footprint to demonstrate the long-term safety and efficacy of its flagship product. Furthermore, the company intends to utilize these resources to strengthen its intellectual property portfolio and establish key partnerships with healthcare providers and distribution networks. As EternaTear continues to refine its therapeutic offerings, the focus will remain on bridging the gap between laboratory innovation and patient-centric medical solutions, ultimately aiming to set a new standard in the management of ocular surface diseases.
See full Eternatear company page
